Ivosidenib Drug Asset Due Diligence Report 2026

This Ivosidenib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

133

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ivosidenib can convert its Small molecule drug profile and IDH1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ivosidenib (query alias: ivosidenib)
Modality / target	Small molecule drug; IDH1; IDH1 inhibitors, Epigenetic drug
Highest global status	Approved
Originator	Celgene Corp.
Active developers	Institut de Recherches Intern Servier, Servier Pharmaceuticals LLC, Servier Bio-Innovation LLC

The MCP disease footprint includes Myelodysplastic Syndromes, IDH1 Mutation Cholangiocarcinoma, IDH1 Mutation Acute Myeloid Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07548710	Phase 2	Recruiting	205	Composite Complete Remission
ChiCTR2600122486	Phase 2	Pending	53	Pathological Complete Response Rate (pCR, ypT0/is ypN0)
NCT07607418	Phase 2	Recruiting	20	Disease free survival (DFS)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML).

Phase 1/2; n=40; evaluation: Positive. Reported fields: ORR = 95.0 %

IVOSIDENIB AS LONG-TERM MAINTENANCE TREATMENT FOR PATIENTS WITH IDH1-MUTATED ACUTE MYELOID LEUKEMIA (AML): A RETROSPECTIVE CASE SERIES

Not Applicable; n=4; evaluation: Positive. Reported fields: Adverse Event: grade 4 neutropenia = Pt 1 experienced grade 4 neutropenia during consolidation

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY IDH1-MUTATED ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB

Not Applicable; n=24; evaluation: Positive. Reported fields: CR+CRi = 25.0 % ; CR+CRi = 29.2 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ivosidenib addresses Myelodysplastic Syndromes, IDH1 Mutation Cholangiocarcinoma, IDH1 Mutation Acute Myeloid Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-12-22	基石药业出售拓舒沃大中华地区和新加坡独家权益	Approved	US$50.0M stated total
	Sagard purchases US royalty interest of Agios' Tibsovo for the treatment of IDH1 mutated AML and cholangiocarcinoma.	Approved	US$131.7M stated total
2020-12-21	Servier to Acquire Agios Pharmaceuticals' Oncology Business	Phase 1	US$1,800.0M upfront; US$200.0M milestones; US$2,000.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Cocrystal of an IDH1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO